Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation

International Journal of Neuropsychopharmacology

Volumn 6, Issue 3, 2003, Pages 247-252

  Kaneda, Yasuhiro ^a,b   Ohmori, Tetsuro ^b  

^a Psychiatric Hospital at Vanderbilt   (United States)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Extrapyramidal symptoms (EPS); Hypothalamo pituitary gonadal (HPG) axis; Plasma homovanillic acid (pHVA); Prolactin (Prl); Psychotic symptoms; Quality of life (QoL); Risperidone; Sexual function

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; HOMOVANILLIC ACID; PROLACTIN; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS GONAD SYSTEM; IMPOTENCE; INSOMNIA; MALE; MOTIVATION; OPEN STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOCIAL PSYCHOLOGY;

EID: 0141892732     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/s146114570300350x     Document Type: Article

References (27)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association.
2. Aymard N, Viala A, Clement M-N, Jacquot M, Vacheron M-N, Gauillard J, Caroli F (2002). Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone: plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26, 975-988.
3. Brown WA, Laughren TP, Williams B (1981). Differential effects of neuroleptic agents on the pituitary-gonadal axis in men. Archives of General Psychiatry 38, 1270-1272.
4. Davidson M, Davis KL (1988). A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Archives of General Psychiatry 45, 561-563.
5. Drachman DA (1977). Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27, 783-790.
6. Franks S, Jacobs HS, Martin N, Nabarro JD (1978). Hyperprolactinaemia and impotence. Clinical Endocrinology 8, 277-287.
7. Friedhoff AJ, Silva RR (1998). The effects of neuroleptics on plasma homovanillic acid. In: Watson Jr. SJ (Ed.), Psychopharmacology: The Fourth Generation of Progress [CD-ROM]. Philadelphia, PA: Lippincott Williams & Wilkins Publishers.
8. Gutierrez MA, Stimmel GL (1999). Management of and counseling for psychotropic drug-induced sexual dysfunction. Pharmacotherapy 19, 823-831.
9. Guy W (1976). ECDU Assessment Manual. Rockville: US Department of Health Education and Welfare.
10. Inada T (1996). Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage [in Japanese]. Tokyo: Seiwa Publisher.
11. Kahn RS, Davis KL (1998). New developments in dopamine and schizophrenia. In: Watson Jr. SJ (Ed.), Psychopharmacology: The Fourth Generation of Progress [CD-ROM]. Philadelphia, PA: Lippincott Williams & Wilkins Publishers.
12. Kaneda Y (2001). Effects of risperidone on gonadal axis hormones in schizophrenia. Annals of Pharmacotherapy 35, 1523-1527.
13. Kaneda Y, Fujii A (2000). Effects of chronic neuroleptic administration on the hypothalamo-pituitary-gonadal axis of male schizophrenics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 24, 251-258.
14. Kaneda Y, Imakura A, Fujii A, Ohmori T (2002a). Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Research 113, 107-113.
15. Kaneda Y, Taniguchi T, Ishimoto Y, Ohmori T (2002b). Effects of atypical antipsychotics on quality of life in patients with schizophrenia [in Japanese]. Seishin Yakuryo Kenkyu Nenpo (Annual Report of Pharmacopsychiatry Research) 34, 93-99.
16. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS (2002). The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. Journal of Pharmacology and Experimental Therapy 302, 1129-1134.
17. Kim YK, Kim L, Lee MS (1999). Risperidone and associated amenorrhea: a report of 5 cases. Journal of Clinical Psychiatry 60, 315-317.
18. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M (1999). Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology 19, 57-61.
19. MacLeod RM, Login IS (1977). Regulation of prolactin secretion through dopamine, serotonin, and the cerebrospinal fluid. Advances in Biochemical Psychopharmacology 16, 147-157.
20. Markianos M, Hatzimanolis J, Lykouras L (1999). Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharmacology (Berlin) 143, 270-272.
21. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE (1994). Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berlin) 114, 9-23.
22. Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychological Reports 10, 799-812.
23. Randrup A, Munkvad I (1972). Evidence indicating an association between schizophrenia and dopaminergic hyperactivity in the brain. Orthomolecular Psychiatry 1, 2-7.
24. Shiwach RS, Carmody TJ (1998). Prolactogenic effects of risperidone in male patients - a preliminary study. Acta Psychiatrica Scandinavica 98, 81-83.
25. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A (2000). Comparative evaluation of typical and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43, 135-145.
26. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, Fitzpatrick R, Jenkinson C (2000). Self-report quality of life measure for people with schizophrenia: the SQLS. British Journal of Psychiatry 177, 42-46.
27. Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC (2002). Sexual side effects of novel antipsychotic medications. Schizophrenia Research 56, 25-30.